Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Other Non-Current Assets data on record, last reported at $721000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 45.95% year-over-year to $721000.0; the TTM value through Sep 2025 reached $721000.0, up 45.95%, while the annual FY2024 figure was $721000.0, 26.71% up from the prior year.
  • Other Non-Current Assets reached $721000.0 in Q3 2025 per STOK's latest filing, roughly flat from $721000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $721000.0 in Q4 2024 and bottomed at $494000.0 in Q2 2024.
  • Average Other Non-Current Assets over 4 years is $599533.3, with a median of $569000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: decreased 13.18% in 2024, then skyrocketed 45.95% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then increased by 26.71% to $721000.0 in 2024, then changed by 0.0% to $721000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $721000.0 in Q3 2025, $721000.0 in Q2 2025, and $721000.0 in Q1 2025.